Skip to main content
SpringerLink
Log in

Quantitative evaluation of PPAR-γ2 Pro12Ala polymorphism with hypertension

Quantitative Auswertung des PPAR-γ2 Pro12Ala Polymorphismus bei Hypertonie

  • Review articles
  • Published:
Herz Aims and scope Submit manuscript

Abstract

Background

The peroxisome proliferator-activated receptor γ2 (PPARγ2)Pro12Ala polymorphism has been reported to be associated with hypertension. However, relevant studies have shown inconsistent results.

Methods

To quantitatively evaluate the relationship between the PPARγ2Pro12Ala polymorphism and hypertension risk, we conducted a meta-analysis based on all available studies selected from Scopus, Web of Science, PubMed, Chinese National Knowledge Infrastructure, and Wanfang databases.

Results

In all, 13 studies were finally included in this meta-analysis. In the allelic model (Ala vs. Pro), the Ala allele of PPARγ2 Pro12Ala polymorphism was associated with hypertension (Odds Ratio [OR] = 0.723, 95% confidence interval [CI] = 0.607–0.861). Sensitivity analysis and exclusion of studies with poor quality scores or controls complicated by other diseases confirmed the validity of this association. Moreover, the PPARγ2Pro12Ala polymorphism was associated with hypertension in the codominant (OR = 0.710, 95% CI = 0.626–0.806), recessive (OR = 0.561, 95% CI = 0.418–0.754), and dominant (OR = 0.693, 95% CI = 0.577–0.833) models.

Conclusion

The Ala allele appears to have a protective effect against hypertension and a dominant function.

Zusammenfassung

Hintergrund

Der Peroxisom-Proliferator-aktivierter-Rezeptor-γ2(PPARγ2)-Pro12Ala-Polymorphismus galt als mit einer Hypertonie assoziiert. Allerdings zeigten relevante Studien inkonsistente Ergebnisse.

Methoden

Zur quantitativen Bewertung der Beziehung zwischen einem PPARγ2-Pro12Ala-Polymorphismus und dem Hypertonierisiko führten die Autoren eine Metaanalyse auf der Grundlage aller verfügbaren Studien aus den Datenbanken Scopus, Web of Science, PubMed, Chinesische Nationale Wissensinfrastruktur-Datenbank und Wanfang durch.

Ergebnisse

In diese Metaanalyse wurden schließlich 13 Studien einbezogen. In dem Allelmodell (Ala vs. Pro) war das Ala-Allel des PPARγ2-Pro12Ala-Polymorphismus mit einer Hypertonie assoziiert (Odds Ratio [OR] = 0,723; 95%-Konfidenzintervall, 95%-KI: 0,607–0,861). Die Sensitivitätsanalyse und der Ausschluss von Studien mit schlechten Qualitätswerten oder von Studien mit Kontrollen, die durch andere Krankheiten kompliziert wurden, bestätigten die Stabilität einer solchen Assoziation. Außerdem war der PPARγ2-Pro12Ala-Polymorphismus im kodominanten (OR = 0,710; 95%-KI: 0,626–0,806), rezessiven (OR = 0,561; 95%-KI: 0,418–0,754) und dominanten (OR = 0,693; 95%-KI: 0,577–0,833) Modell mit einer Hypertonie assoziiert.

Schlussfolgerung

Das Ala-Allel scheint eine schützende Wirkung gegen Bluthochdruck aufzuweisen und in seiner Funktion dominant zu sein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Freeman AJ, Vinh A, Widdop RE (2017) Novel approaches for treating hypertension. F1000Res 6:80

    Article  PubMed  PubMed Central  Google Scholar 

  2. Brody AM, Kumar VA, Levy PD (2017) Hot topic: global burden of treating hypertension-what is the role of the emergency department? Curr Hypertens Rep 19(1):8

    Article  PubMed  Google Scholar 

  3. Yang L, Tian RG, Chang PY, Yan MR et al (2015) Association of SNPs in the PPARgamma gene and hypertension in a Mongolian population. Genet Mol Res 14(4):19295–19308

    Article  CAS  PubMed  Google Scholar 

  4. Luft FC (2017) What have we learned from the genetics of hypertension? Med Clin North Am 101(1):195–206

    Article  PubMed  Google Scholar 

  5. Roszer T, Ricote M (2010) PPARs in the renal regulation of systemic blood pressure. PPAR Res 2010:698730. https://doi.org/10.1155/2010/698730

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gao L, Wang L, Yun H, Su L et al (2010) Association of the PPARgamma2 gene Pro12Ala variant with primary hypertension and metabolic lipid disorders in Han Chinese of Inner Mongolia. Genet Mol Res 9(3):1312–1320

    Article  CAS  PubMed  Google Scholar 

  7. Iglarz M, Touyz RM, Amiri F, Lavoie MF et al (2003) Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol 23(1):45–51

    Article  CAS  PubMed  Google Scholar 

  8. Diep QN, Amiri F, Benkirane K, Paradis P et al (2004) Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol 82(11):976–985

    Article  CAS  PubMed  Google Scholar 

  9. Benkirane K, Viel EC, Amiri F, Schiffrin EL (2006) Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3‑kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47(1):102–108

    Article  CAS  PubMed  Google Scholar 

  10. Tamori Y, Masugi J, Nishino N, Kasuga M (2002) Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51(7):2045–2055

    Article  CAS  PubMed  Google Scholar 

  11. Bener A, Darwish S, Al-Hamaq AO, Mohammad RM et al (2013) Association of PPARgamma2 gene variant Pro12Ala polymorphism with hypertension and obesity in the aboriginal Qatari population known for being consanguineous. Appl Clin Genet 6:103–111

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M et al (2005) Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. J Hypertens 23(2):301–308

    Article  CAS  PubMed  Google Scholar 

  13. Gu SJ, Guo ZR, Wu M, Ding Y et al (2013) Association of peroxisome proliferator-activated receptor gamma polymorphisms and haplotypes with essential hypertension. Genet Test Mol Biomarkers 17(5):418–423

    Article  CAS  PubMed  Google Scholar 

  14. Horiki M, Ikegami H, Fujisawa T, Kawabata Y et al (2004) Association of Pro12Ala polymorphism of PPARgamma gene with insulin resistance and related diseases. Diabetes Res Clin Pract 66(Suppl 1):S63–S67

    Article  CAS  PubMed  Google Scholar 

  15. Hui P, Nakayama T, Morita A, Sato N et al (2007) Common single nucleotide polymorphisms in Japanese patients with essential hypertension: aldehyde dehydrogenase 2 gene as a risk factor independent of alcohol consumption. Hypertension 30(7):585–592

    CAS  Google Scholar 

  16. Kim K, Lee S, Valentine RJ (2007) Association of pro12Ala polymorphism in the peroxisome proliferative-activated receptor gamma2 gene with obesity and hypertension in Korean women. J Nutr Sci Vitaminol 53(3):239–246

    Article  CAS  PubMed  Google Scholar 

  17. Lu Z, Dong B, Mo X, Chen T et al (2008) Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians. Exp Gerontol 43(12):1108–1113

    Article  CAS  PubMed  Google Scholar 

  18. Ostgren CJ, Lindblad U, Melander O, Melander A et al (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: skaraborg hypertension and diabetes project. J Hypertens 21(9):1657–1662

    Article  PubMed  Google Scholar 

  19. Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F (2003) Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens 21(9):1649–1655

    Article  CAS  Google Scholar 

  20. Sookoian S, Garcia SI, Porto PI, Dieuzeide G et al (2005) Peroxisome proliferator-activated receptor gamma and its coactivator-1 alpha may be associated with features of the metabolic syndrome in adolescents. J Mol Endocrinol 35(2):373–380

    Article  CAS  PubMed  Google Scholar 

  21. Wang G, Xu P, Feng W, Jiang X et al (2015) Case-control study on peroxisome proliferator-activated receptor gamma polymorphism and interaction with HDL on essential hypertension in Chinese Han. Iran J Basic Med Sci 18(12):1228–1232

    PubMed  PubMed Central  Google Scholar 

  22. Zhang A, Zhang M, Zhang J, Yu Y et al (2005) The influence of the Pro12Ala mutation of PPARgamma2 receptor gene on beta-cells restoration and insulin resistance in type 2 diabetes with hypertension. J Huazhong Univ Sci Technol Med Sci 25(6):648–650

    Article  CAS  PubMed  Google Scholar 

  23. Shen D, Ha DW (2004) Relationship between PPAR γ2 gene pro12Ala polymorphism hypertension and blood lipids. Chin J Hypertens 12(4):319–322

    Google Scholar 

  24. Dong HR, Han FQ, Su XL (2012) The relationship between peroxis ome proliferator-activated receptor γ and its coactivated 1α and mongolian hypertension. Int J Lab Med 33(22):2698–2700

    CAS  Google Scholar 

  25. Chen J, Zhang M, Liu JM, Ma RL et al (2014) Association of PPARγ gene polymorphism with hypertension in Xinjiang Uygur. J Pract Med 30(18):2922–2925

    CAS  Google Scholar 

  26. Pan HJ, Guo YY, Wang G, Zhao L et al (2007) Additive effects of the variants in the β3-AR and PPAR-γ2 genes on essential hypertension in Xinjiang kazakh population. Chin J Birth Health Hered 15(3):19–21

    Google Scholar 

  27. Wang Y, Liu C (2012) Quantitative evaluation of common polymorphism (rs1801282) in the PPARgamma2 gene and hypertension susceptibility. Gene 502(2):159–162

    Article  CAS  PubMed  Google Scholar 

  28. Hou X, Chen X, Shi J (2015) Genetic polymorphism of MTHFR C677T and premature coronary artery disease susceptibility: a meta-analysis. Gene 565(1):39–44

    Article  CAS  PubMed  Google Scholar 

  29. Yang W, Zhu Z, Wang J, Ye W et al (2015) Evaluation of the relationship between T663A polymorphism in the alpha-epithelial sodium channel gene and essential hypertension. Saudi Med J 36(9):1039–1045

    Article  PubMed  PubMed Central  Google Scholar 

  30. Yliharsila H, Eriksson JG, Forsen T, Laakso M et al (2004) Interactions between peroxisome proliferator-activated receptor-gamma 2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication. J Hypertens 22(7):1283–1287

    Article  CAS  PubMed  Google Scholar 

  31. Takeda K, Ichiki T, Tokunou T, Funakoshi Y et al (2000) Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102(15):1834–1839

    Article  CAS  PubMed  Google Scholar 

  32. Ji Y, Liu J, Wang Z, Liu N et al (2009) PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest 89(8):887–902

    Article  CAS  PubMed  Google Scholar 

  33. Sugawara A, Takeuchi K, Uruno A, Ikeda Y et al (2001) Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142(7):3125–3134

    Article  CAS  PubMed  Google Scholar 

  34. Lehrke M, Lazar MA (2005) The many faces of PPARgamma. Cell 123(6):993–999

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Shanghai University Young Teacher Training Program (ZZJKYX15021).

Author information

Authors and Affiliations

  1. School of Pharmacy, Shanghai University of Medicine & Health Sciences, 201318, Shanghai, China

    W. Yang, J. Wang & W. Ye

  2. Bio-ID Center, School of Biomedical Engineering, Shanghai Jiao Tong University, 200240, Shanghai, China

    X. Li

Authors
  1. W. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X. Li.

Ethics declarations

Conflict of interest

W. Yang, J. Wang, W. Ye, and X. Li declare that they have no competing interests.

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, W., Wang, J., Ye, W. et al. Quantitative evaluation of PPAR-γ2 Pro12Ala polymorphism with hypertension. Herz 43, 719–727 (2018). https://doi.org/10.1007/s00059-017-4618-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-017-4618-6

Keywords

Schlüsselwörter

Search

Navigation